DII dói. DII isola. DII cansa. Mas também fortalece.
Em breve começa o #MaioRoxo da ALEMDII — feito por quem vive com Doença de Crohn e Retocolite Ulcerativa.
Porque o que não se vê, precisa ser dito.
Nossa jornada importa.
Did you know the Shield test is a blood test that was recently approved by @US_FDA as a new screening method for #colorectalcancer ? 👏🏽
Given the increasing incidence of #CRC, learn more about the Shield test. Don't forget to discuss with your physician which test is appropriate for your care!💥
The questions you ask are so important. I suspect there is a lot of over treatment and over diagnosis for #IBD. However, the issue with this kind of very large study is that it aggregates a lot of very heterogeneous subtypes of disease.
I suspect you are right that we make almost no dent in the rate of surgery for ileal structuring disease no matter how early we treat or what drug we use. But I do think we can reduce risk of surgery more substantially with severe colonic disease and perianal disease with early, aggressive therapy.
Another nuance to this is when a patient presents after diagnosis (time from Dx to treatment) may not reflect the burden of disease at that time - some patients have clearly had CD for years with bowel damage present although they may have only been just diagnosed formally a few months ago.
For UC I have little doubt the rate of colectomy is dropping and this has been shown in other studies @gilkaplan. However, again reducing risk of surgery in UC is highly unlikely to be related to how soon advanced therapies are introduced after diagnosis. It's how we use those therapies in people whose UC starts to escalate in severity or who end up in hospital.
So there are some useful messages in this study but to me the bottom line is it's not about how soon after diagnosis the advanced therapies are introduced - it's about knowing which patients need an early aggressive approach and doing it well.
#AOVIVO | A Comissão de Legislação Participativa da Câmara está reunida em audiência pública para debater sobre a criação de centros de terapia assistida no SUS. Assista: https://t.co/QbxMwbcbKF
📣É HOJE 📣Desafios da jornada do paciente com Artrite Reumatoide 🗣Perspectiva do Médico e do Paciente
🌐 Transmissão
🌐 Fanpage Artrite Reumatoide - Grupar-BR
🌐 Instagram: @artritereumatoide
🌐 Youtube Artrite Reumatoide: https://t.co/l0QaeFPnrk
@DeviousDwyer@MondayNightIBD I never had to take them for too long, SE: mainly moon face and weight, but I it was good for my appearance and self-esteem. I was very thin when I used
🗣Aula 7 - Cuidado Farmacêutico no gerenciamento das doenças crônicas - entenda o que é a assistência farmacêutica no SUS, a dinâmica das farmácias de alto custo e o papel do farmacêutico na linha de cuidado.
#cursoinfluencerdasaude
🗣Aula 8:Uso Racional de Medicamentos e Polifar PUBLICAR AGORA mácia - como podemos melhorar o relacionamento do paciente crônico com a sua jornada no uso de medicamentos.
⏰Data: 25/10 às 20h
#cuidadofarmaceutico
#veja todas as informações solicitadas no requerimento de Informação 2397/2023 - anexo nas próximas imagens👉👉
.
#saiba mais no #Blog da @biored_br https://t.co/J1c1XfMJPJ
🗣A importância da cocriação com os pacientes para melhores resultados clínicos, explicados por Kelly Cristina Rodrigues da Patient Centricity
⏰20/09 às 20h 📲 Zoom Meeting - link de acesso enviado por email para todos os inscritos
#influencerdasaude#blogueirosdasaude
📌Curso de Ferramentas Virtuais Participativas promovido pelo Projeto Participa +
.
👉Faça sua inscrição e participe da terceira edição do "Projeto Formação para o Controle Social no SUS"
.
👉A inscrição deverá ser realizada através do link: https://t.co/3HrOEOUzEP .